The United States Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has scheduled a meeting on December 5, 2007 to discuss the new indication submitted with the supplemental biologics license application (sBLA) for Genentech’s targeted agent Avastin (bevacizumab).
Avastin is a monoclonal antibody that is targeted against the vascular endothelial growth factor receptor (VEGF). The new indication specifies Avastin to be used for treatment of patients with locally recurrent or metastatic HER2-negative breast cancer who have not received prior therapy for their stage of disease.
Avastin is currently approved for treatment of colorectal cancer and non-small cell lung cancer.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
